MedElevator Войти в исследования
← Поиск публикаций

DOI 10.2147/jaa.s337284

Медицинская библиотека · Journal of asthma and allergy · 2022

Efficacy and Safety of Masitinib in Corticosteroid-Dependent Severe Asthma: A Randomized Placebo-Controlled Trial.

Davidescu Lavinia, Ursol Grigoriy, Korzh Oleksii, Deshmukh Vikranth, Kuryk Lesia, Nortje Monja-Marie, Godlevska Olga, Devouassoux Gilles, Khodosh Eduard, Israel Elliot, Moussy Alain, Mansfield Colin D, Hermine Olivier, Chanez Pascal

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Masitinib is an oral tyrosine kinase inhibitor that selectively targets mast cell activity and platelet-derived growth factor receptor (PDGFR) signaling, both of which are implicated in various mechanisms of asthma pathogenesis.

OBJECTIVE

Assessment of masitinib as an add-on to standard maintenance therapy as compared with placebo in the treatment of oral corticosteroid-dependent severe asthma.

METHODS

We conducted a randomized (2:1), placebo-controlled study of masitinib (6 mg/kg/d) in adults with severe asthma uncontrolled by high dose inhaled corticosteroids and long-acting beta-adrenoreceptor agonists plus oral corticosteroids (OCS) (≥7.5 mg/d). No minimum baseline blood eosinophil count was specified. Following a protocol amendment, the primary endpoint was reduction of annualized severe asthma exacerbation rate adjusted for the overall time on treatment (SAER). Subgroup analysis according to yearly cumulative OCS intake was also performed, a higher OCS dose indicating more severe asthma that is harder to control.

RESULTS

Following an average exposure of approximately 13 months, masitinib (n = 240) reduced the SAER by 35% relative to placebo (n = 115) (rate ratio (RR) 0.65 (95% CI [0.47-0.90]; P = 0.010)). For patients with eosinophil ≥150 cell/µL, masitinib (n = 181) reduced SAER by 38% relative to placebo (n = 87); RR 0.62 (95% CI [0.42-0.91]; P = 0.016). Benefit of masitinib was shown to increase in the most severely affected patients (OCS intake of >1000 mg/year), with a significant (P < 0.01) reduction in SAER of 50%-70%. Safety was consistent with the known masitinib profile.

CONCLUSION

Orally administered masitinib reduces the risk of asthma exacerbations in severe asthma patients, with an acceptable safety profile. Masitinib may potentially provide a new treatment option for oral corticosteroid-dependent severe asthma.

Для цитирования: Davidescu Lavinia, Ursol Grigoriy, Korzh Oleksii, Deshmukh Vikranth, Kuryk Lesia, Nortje Monja-Marie, Godlevska Olga, Devouassoux Gilles, Khodosh Eduard, Israel Elliot, Moussy Alain, Mansfield Colin D, Hermine Olivier, Chanez Pascal. Efficacy and Safety of Masitinib in Corticosteroid-Dependent Severe Asthma: A Randomized Placebo-Controlled Trial.. Journal of asthma and allergy. 2022. DOI: 10.2147/jaa.s337284.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.